Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24239210

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2013 Dec
First author
Buzdar AU

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Dec;14(13):1250-1. doi: 10.1016/S1470-2045(13)70536-9.
    note
    Source null
    related pmid
    24239207
    relationship
    Comment in
  2. citation
    Strahlenther Onkol. 2014 Apr;190(4):428-9. doi: 10.1007/s00066-014-0558-8.
    note
    Source null
    related pmid
    24638245
    relationship
    Comment in

Authors and identifiers

  1. name
    Buzdar AU
    type
    Author
  2. name
    Suman VJ
    type
    Author
  3. name
    Meric-Bernstam F
    type
    Author
  4. name
    Leitch AM
    type
    Author
  5. name
    Ellis MJ
    type
    Author
  6. name
    Boughey JC
    type
    Author
  7. name
    Unzeitig G
    type
    Author
  8. name
    Royce M
    type
    Author
  9. name
    McCall LM
    type
    Author
  10. name
    Ewer MS
    type
    Author
  11. name
    Hunt KK
    type
    Author
  12. name
    American College of Surgeons Oncology Group investigators
    type
    CollectiveName
Complete bibliographic record and source provenance
authors
  1. name
    Buzdar AU
    type
    Author
  2. name
    Suman VJ
    type
    Author
  3. name
    Meric-Bernstam F
    type
    Author
  4. name
    Leitch AM
    type
    Author
  5. name
    Ellis MJ
    type
    Author
  6. name
    Boughey JC
    type
    Author
  7. name
    Unzeitig G
    type
    Author
  8. name
    Royce M
    type
    Author
  9. name
    McCall LM
    type
    Author
  10. name
    Ewer MS
    type
    Author
  11. name
    Hunt KK
    type
    Author
  12. name
    American College of Surgeons Oncology Group investigators
    type
    CollectiveName
bibliography ids
  1. nci-bib-0ca3965d458e0eb4f580ab77
book metadata
content sha256
e62498f70d4b9993f315cf83cdc64a9aba9cbe3599691a1adf83d6f26c270655
document type
citation
dois
  1. 10.1016/S1470-2045(13)70502-3
electronic publication date
display
2013 Nov 13
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:24239210
immutable id
pubmed:24239210@e62498f70d4b9993f315cf83cdc64a9aba9cbe3599691a1adf83d6f26c270655
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
13
name
The Lancet. Oncology
nlm unique id
100957246
pages
1317-25
volume
14
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2013 Dec;14(13):1250-1. doi: 10.1016/S1470-2045(13)70536-9.
    note
    Source null
    related pmid
    24239207
    relationship
    Comment in
  2. citation
    Strahlenther Onkol. 2014 Apr;190(4):428-9. doi: 10.1007/s00066-014-0558-8.
    note
    Source null
    related pmid
    24638245
    relationship
    Comment in
outcomes validated
false
pmid
24239210
provenance
batch id
af10498814d931b53231
provider
NCBI PubMed ESummary
record sha256
63524b09ce1af1db8d9335782212e8472e112099c20eb6d6ba2ecb7559c330f2
response sha256
077a09272afe77e74d5ff01cb33335ddb8a638b7afbafb70ec20e837a0c85c7f
retrieved at
2026-09-09T23:47:00.193465+00:00
publication date
display
2013 Dec
precision
month
year
2013
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24239210/
title
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Preserved source evidence · Not medical advice